Skip to Content

LY22-02b

Main Content

Efficacy and safety of CD19 directed CAR T-cell therapy for T-cell rich histiocyte rich B-cell lymphoma.

Study #: LY22-02b

Study Status: Published

Presentation(s)

2024, Tandem (Poster)

CD19-directed CART therapy for T cell/histiocyte rich large B-cell lymphoma.

Citation

Pophali PA, Fein JA, Ahn KW, Allbee-Johnson M, Ahmed N, Awan FT, Farhan S, Grover NS, Hilal T, Iqbal M, Maakaron J, Modi D, Nasrollahi E, Schachter L, Sauter CS, Hamadani M, Herrera AF, Shouval R, Shadman M.

Blood Advances. 2024, Oct 22: 8(20): 8(20):5290-5296. doi: 10.1182/bloodadvances.2024013863. Epub 2024, Jul 14. PMCID:PMC11497379.

PubMed

PMID: 38985302

Abstract